CareDx Inc (CDNA.OQ)

About

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	--
Market Cap(Mil.):	$126.68
Shares Outstanding(Mil.):	22.54
Dividend:	--
Yield (%):	--

Financials

Latest News about CDNA.OQ

BRIEF-Caredx Enters Into A Credit Agreement And Guaranty - SEC Filing

* CAREDX SAYS ON APRIL 17 ENTERED INTO A CREDIT AGREEMENT AND GUARANTY - SEC FILING

18 Apr 2018

BRIEF-Caredx Launches Heartcare For Heart Transplant Recipients

* ANNOUNCED LAUNCH OF HEARTCARE, A COMPREHENSIVE REJECTION SURVEILLANCE SOLUTION FOR HEART TRANSPLANT RECIPIENTS Source text for Eikon: Further company coverage:

10 Apr 2018

BRIEF-CareDx Q4 Non-Gaap Loss Per Share $0.09

* FY2018 REVENUE VIEW $61.5 MILLION -- THOMSON REUTERS I/B/E/S

23 Mar 2018

BRIEF-Caredx - Entered Binding Commitment With Perceptive Advisors For Term Loan Of Between $15 Mln And $35 Mln

* CAREDX - ENTERED BINDING COMMITMENT WITH PERCEPTIVE ADVISORS FOR A TERM LOAN OF BETWEEN $15 MILLION AND $35 MILLION

01 Mar 2018

BRIEF-Caredx Sees FY 2017 Revenue $48.1 Mln To $48.3 Mln

* CAREDX REPORTS PRELIMINARY FOURTH QUARTER AND FY2017 FINANCIAL RESULTS

08 Jan 2018

BRIEF-Caredx reports third quarter loss of $0.63 per share

* Sees fy 2017 revenue $47 million to $49 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

10 Nov 2017

BRIEF-Biocardia announces reverse stock split and release of indemnity holdback shares

* Biocardia announces reverse stock split and release of indemnity holdback shares

02 Nov 2017

» More CDNA.OQ News

Competitors

	Price	Chg
Ardea Biosciences, Inc. (RDEA.OQ)	--	--
Nanosphere, Inc. (NSPH.OQ)	--	--